{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:36:59Z","timestamp":1773250619587,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"26","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.064","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:02:02Z","timestamp":1526515322000},"page":"3727-3732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines"],"prefix":"10.1016","volume":"36","author":[{"given":"Emile F.F.","family":"Jonker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari\u00ebtte B.","family":"van Ravenhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy A.M.","family":"Berbers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo G.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.064_b0005","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/IDR.S12716","article-title":"Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive disease","volume":"4","author":"Broker","year":"2011","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.vaccine.2018.05.064_b0010","unstructured":"WHO. Fact Sheet Meningococcal Meningitis, January 2018."},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.05.064_b0015","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.064_b0020","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.05.064_b0025","doi-asserted-by":"crossref","first-page":"B30","DOI":"10.1016\/j.vaccine.2009.05.003","article-title":"Quadrivalent meningococcal conjugate vaccines","volume":"27","author":"Pace","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.064_b0030","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.16.18-00158","article-title":"Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018","volume":"23","author":"Knol","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2018.05.064_b0035","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jinf.2015.09.035","article-title":"The introduction of the meningococcal B (MenB) vaccine (Bexsero(R)) into the national infant immunisation programme\u2013New challenges for public health","volume":"71","author":"Ladhani","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2018.05.064_b0040","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1586\/14760584.7.8.1201","article-title":"Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice","volume":"7","author":"Nicolas","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.05.064_b0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/jidsymp.2011.5","article-title":"The cutaneous vascular system in chronic skin inflammation","volume":"15","author":"Huggenberger","year":"2011","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1016\/j.vaccine.2018.05.064_b0050","unstructured":"Hickling JK, Jones KR. PATH: Intradermal delivery of vaccines, a review of the literature and the potential for development for use in low- and middleincome countries; 2009."},{"key":"10.1016\/j.vaccine.2018.05.064_b0055","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1128\/CVI.00478-07","article-title":"Development of a fluorescent-bead-based multiplex immunoassay to determine immunoglobulin G subclass responses to Neisseria meningitidis serogroup A and C polysaccharides","volume":"15","author":"de Voer","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2018.05.064_b0060","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jim.2008.02.018","article-title":"Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus","volume":"335","author":"van Gageldonk","year":"2008","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2018.05.064_b0065","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1128\/IAI.69.3.1568-1573.2001","article-title":"Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection","volume":"69","author":"Borrow","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2018.05.064_b0070","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2013serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.064_b0075","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.05.064_b0080","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1128\/CDLI.4.2.156-167.1997","article-title":"Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group","volume":"4","author":"Maslanka","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.05.064_b0085","doi-asserted-by":"crossref","first-page":"4753","DOI":"10.1016\/j.vaccine.2017.06.007","article-title":"Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: optimal age for vaccination","volume":"35","author":"van Ravenhorst","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.064_b0090","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.vaccine.2017.06.053","article-title":"Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: a randomized controlled trial","volume":"35","author":"van Ravenhorst","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.064_b0095","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/INF.0b013e3181b9a831","article-title":"A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.064_b0100","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/INF.0b013e3181d9e653","article-title":"Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life","volume":"29","author":"Diez-Domingo","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.064_b0105","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1016\/j.vaccine.2013.07.083","article-title":"Effectiveness of meningococcal serogroup C vaccine programmes","volume":"31","author":"Borrow","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.064_b0110","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/ciu601","article-title":"A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination","volume":"59","author":"Bijlsma","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.064_b0115","doi-asserted-by":"crossref","first-page":"6309","DOI":"10.1016\/j.vaccine.2016.10.049","article-title":"Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination","volume":"34","author":"van Ravenhorst","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.064_b0120","doi-asserted-by":"crossref","DOI":"10.1093\/jtm\/tax033","article-title":"Single visit rabies pre-exposure priming induces a robust anamnestic antibody response after simulated post-exposure vaccination: results of a dose-finding study","volume":"24","author":"Jonker","year":"2017","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2018.05.064_b0125","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-3083.2011.02535.x","article-title":"Fractional Doses Vaccine Study G. Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A\/C\/Y\/W135 polysaccharide vaccine","volume":"74","author":"Barnes","year":"2011","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2018.05.064_b0130","doi-asserted-by":"crossref","first-page":"6974","DOI":"10.1016\/j.vaccine.2009.09.082","article-title":"Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults","volume":"27","author":"de Voer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.064_b0135","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1371\/journal.pntd.0000342","article-title":"Immunogenicity of fractional doses of tetravalent a\/c\/y\/w135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda","volume":"2","author":"Guerin","year":"2008","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18307047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T02:38:52Z","timestamp":1604284732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18307047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":27,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18307047"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.064","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of fractional dose intradermal injection of two quadrivalent conjugated meningococcal vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}